Please login to the form below

Not currently logged in
Email:
Password:

Quintiles recruits ex-Merck Serono development head

Dr Christoph Schnorr joins European R&D consulting practice

Quintiles Dr Christoph SchnorrDr Christoph Schnorr has joined Quintiles as head of its European R&D consulting practice.

He was formerly head of development operations at Merck Serono, where he had oversight for all development functions including medical science and innovation, global clinical operations, the chief medical office and regulatory affairs.

Prior to joining Merck Serono in 2008, Dr Schnorr was a partner in Accenture's health and life science practice, where he focused on R&D initiatives, business process and organisational design, and performance.

A physician by training, and with twenty years' experience in the pharmaceutical industry, Quintiles praised Dr Schnorr's extensive expertise across the whole drug development spectrum.

24th October 2012

From: Research

Share

Tags

Featured jobs

Senior Brand Manager - Harlow
Competitive
Sales Manager - Media Publishing – Cheshire
25,000 to 35,000 per annum
UK Marketing Director
80,000 to 100,000 per annum
Group Account Director –Healthcare Advertising
Neg

Subscribe to our email news alerts

PMHub

Add my company
Galbraith Wight

The GalbraithWight Business School deliver boths in-house and public training programmes including the only accredited diploma designed specifically to enable ...

Latest intelligence

Online Physician Communities
How can pharma deliver returns on increased digital investment?
Independent online professional networks work best as part of a multi-channel campaign  ...
The impact of Hollande's healthcare reforms in France
A tougher environment for pharma, with market access and regulatory challenges...
Customer-centred_multichannel_marketing_-_419x336.png
A guide to developing customer-centred, multichannel marketing
Find out how a balanced approached to multichannel marketing could benefit your brand - the customer's agenda is just as important as Pharma's and needs to be listened to in ...